Engineering CRISPR, Stem Cells, and CAR T to Transform Existing Biology into Disease Cures
DOI:
https://doi.org/10.58445/rars.2886Keywords:
CRISPR, Stem Cells, CAR T-cell therapyAbstract
In recent years, strides have been made in medical technology that may shift the paradigm of the field as a whole. Complex treatments like CRISPR therapy, stem cell therapy, and CAR T-cell therapy have been made more effective and more easily accessible. With so many ailments afflicting people across the world, one of these three modern medicine technologies may act as a cure. This paper is a literature review, detailing both the benefits and current drawbacks of each form of treatment. In addition, the long term potentials of these treatments are discussed. Following a description of each of the technologies and their respective therapies, ongoing trials combining them in an attempt to be more effective overall are discussed. All three of these treatments are useful in different cases, and when used together, they have the potential to help a lot of people.
References
Aly, R. M. (2020). Current state of stem cell-based therapies: An overview. Stem Cell Investigation, 7, 8–8. https://doi.org/10.21037/sci-2020-001
Ben Jehuda, R., Shemer, Y., & Binah, O. (2018). Genome editing in induced pluripotent stem cells using CRISPR/Cas9. Stem Cell Reviews and Reports, 14(3), 323–336. https://doi.org/10.1007/s12015-018-9811-3
De Masi, C., Spitalieri, P., Murdocca, M., Novelli, G., & Sangiuolo, F. (2020). Application of CRISPR/Cas9 to human-induced pluripotent stem cells: From gene editing to drug discovery. Human Genomics, 14(1). https://doi.org/10.1186/s40246-020-00276-2
“FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease.” U.S. Food and Drug Administration, FDA, 8 Dec. 2023, www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease.
Kim, E. J., Kang, K. H., & Ju, J. H. (2017). CRISPR-Cas9: A promising tool for gene editing on induced pluripotent stem cells. The Korean Journal of Internal Medicine, 32(1), 42–61. https://doi.org/10.3904/kjim.2016.198
Kozovska, Z., Rajcaniova, S., Munteanu, P., Dzacovska, S., & Demkova, L. (2021). CRISPR: History and perspectives to the future. Biomedicine & Pharmacotherapy, 141, 111917. https://doi.org/10.1016/j.biopha.2021.111917
Krishna, S., & Kantipudi, S. (2019). Gene editing nucleases - zfns, Talens and CRISPR. Chettinad Health City Medical Journal, 8(4). https://doi.org/10.36503/chcmj8(4)-06
Li, C., Mei, H., & Hu, Y. (2020). Applications and explorations of CRISPR/Cas9 in car T-cell therapy. Briefings in Functional Genomics, 19(3), 175–182. https://doi.org/10.1093/bfgp/elz042
Li, X., Xu, S., Fuhrmann-Aoyagi, M. B., Yuan, S., Iwama, T., Kobayashi, M., & Miura, K. (2022). CRISPR/Cas9 technique for temperature, drought, and salinity stress responses. Current Issues in Molecular Biology, 44(6), 2664–2682. https://doi.org/10.3390/cimb44060182
Locke, L. G. (2020). The promise of CRISPR for human germline editing and the perils of “Playing god.” The CRISPR Journal, 3(1), 27–31. https://doi.org/10.1089/crispr.2019.0033
Moradi, S., Mahdizadeh, H., Šarić, T., Kim, J., Harati, J., Shahsavarani, H., Greber, B., & Moore, J. B. (2019). Research and therapy with induced pluripotent stem cells (ipscs): Social, legal, and ethical considerations. Stem Cell Research & Therapy, 10(1). https://doi.org/10.1186/s13287-019-1455-y
Ozkan, J. (2021). Jennifer A. Doudna and Emmanuelle Charpentier. European Heart Journal, 42(22), 2143–2145. https://doi.org/10.1093/eurheartj/ehaa1054
Scientific Image and Illustration Software. BioRender. (n.d.). https://www.biorender.com/
Sengsayadeth, S., Savani, B. N., Oluwole, O., & Dholaria, B. (2021). Overview of approved car‐t therapies, ongoing clinical trials, and its impact on clinical practice. eJHaem, 3(S1), 6–10. https://doi.org/10.1002/jha2.338
Sterner, R. C., & Sterner, R. M. (2021). CAR T-cell therapy: Current limitations and potential strategies. Blood Cancer Journal, 11(4). https://doi.org/10.1038/s41408-021-00459-7
Volarevic, V., Markovic, B. S., Gazdic, M., Volarevic, A., Jovicic, N., Arsenijevic, N., Armstrong, L., Djonov, V., Lako, M., & Stojkovic, M. (2018). Ethical and safety issues of stem cell-based therapy. International Journal of Medical Sciences, 15(1), 36–45. https://doi.org/10.7150/ijms.21666
Waddington, S. N., Privolizzi, R., Karda, R., & O’Neill, H. C. (2016). A broad overview and review of CRISPR-Cas Technology and Stem Cells. Current Stem Cell Reports, 2(1), 9–20. https://doi.org/10.1007/s40778-016-0037-5
Wang, J. Y., & Doudna, J. A. (2023). CRISPR technology: A Decade of genome editing is only the beginning. Science, 379(6629). https://doi.org/10.1126/science.add8643
Wang, M., Xu, X., Lei, X., Tan, J., & Xie, H. (2021). Mesenchymal stem cell-based therapy for burn wound healing. Burns & Trauma, 9. https://doi.org/10.1093/burnst/tkab002
Yamanaka, S. (2020). Pluripotent stem cell-based cell therapy—promise and challenges. Cell Stem Cell, 27(4), 523–531. https://doi.org/10.1016/j.stem.2020.09.014
YAN, Y., AUMANN, R. A., HÄCKER, I., & SCHETELIG, M. F. (2023). CRISPR-based genetic control strategies for insect pests. Journal of Integrative Agriculture, 22(3), 651–668. https://doi.org/10.1016/j.jia.2022.11.003
Zakrzewski, W., Dobrzyński, M., Szymonowicz, M., & Rybak, Z. (2019). Stem cells: Past, present, and future. Stem Cell Research & Therapy, 10(1). https://doi.org/10.1186/s13287-019-1165-5
Downloads
Posted
Categories
License
Copyright (c) 2025 Gurpriya Gandham
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.